New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.
Based on centrally diagnosed 3528 patients in the Düsseldorf registry, we validated the new proposals for the classification of the MDS by the WHO working group: 256 patients were diagnosed as MDSSLD (7,3%), 978 MDSMLD (27,7%), 227 MDS RS SLD (6,4%); 321 MDS RS MLD (9,1%), 159 MDS del(5q) (4,5%), 481 MDSEB 1 (13,6%), 620 MDSEB 2 (17,6%), and 148 MDS-U (4,2%). 352 patients (16,9% of the non blastic types) changed the category, mainly moving from RCMD to MDS RS MLD, RCUD and RCMD to MDS del(5q). Median survival times of the refined groups differed from more than 60 months in the MDSSLD (RS) groups, 37 months in the MDSMLD (RS) groups, 79 months of the MDS del(5q) group and 21 and 11 months in the MDSEB 1 and 2 groups, respectively. The difference between the groups with regard to the risk of AML evolution was also impressing. No major changes were made with regard to the MDS-U categories. In summary, the proposals of the WHO group for the classification of MDS are thoughtful, taking into account biologic parameters of the diseases, a more precise wording, to some extend pragmatic and feasible.
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany. Electronic address: c.strupp@web.de.
Corinna
C
Strupp
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
Kathrin
K
Nachtkamp
Department of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany.
Barbara
B
Hildebrandt
Marienhospital, Department of Oncology and Hematology, Düsseldorf, Germany.
Aristoteles
A
Giagounidis
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
Rainer
R
Haas
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
Norbert
N
Gattermann
James P. Wilmot Cancer Institute, Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
John M
JM
Bennett
Department of Hematology, Oncology and Clinical Immunology, St. Johannes Hospital, Duisburg, Germany.
Carlo
C
Aul
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
Ulrich
U
Germing
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002471:Cell Transformation, Neoplastic; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000145:classification* / Q000175:diagnosis* / Q000401:mortality; D012042:Registries; D015996:Survival Rate; D014944:World Health Organization; D055815:Young Adult
Classification; Myelodysplastic syndromes; Prognosis; Subtypes